{{DISPLAYTITLE:''N''-Phenylacetyl-<small>L</small>-prolylglycine ethyl ester}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 424810394
| IUPAC_name = Ethyl 1-(phenylacetyl)-<small>L</small>-prolylglycinate
| image = Noopept.svg
| width = 220
| image2 = Noopept.png

<!--Clinical data-->
| tradename = Noopept
| pregnancy_AU = <!-- A, B1, B2, B3, C, D, X -->
| pregnancy_US = <!-- A, B, C, D, X -->
| legal_AU = <!-- Unscheduled, S2, S3, S4, S5, S6, S7, S8, S9 -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, Class A, B, C -->
| legal_US = Unscheduled
| legal_US_comment = Not FDA approved
| legal_status = 

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 157115-85-0
| PubChem = 180496
| synonyms = ''N''-Phenylacetyl-<small>L</small>-prolylglycine ethyl ester; GVS-111

<!--Chemical data-->
| C=17 | H=22 | N=2 | O=4 
| molecular_weight = 318.367 g/mol
| SMILES = c2ccccc2CC(=O)N1CCC[C@@H]1C(=O)NCC(=O)OCC
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 157065
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C17H22N2O4/c1-2-23-16(21)12-18-17(22)14-9-6-10-19(14)15(20)11-13-7-4-3-5-8-13/h3-5,7-8,14H,2,6,9-12H2,1H3,(H,18,22)/t14-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = PJNSMUBMSNAEEN-AWEZNQCLSA-N
}}

'''Omberacetam''' (brand name '''Noopept''' ({{lang-ru|Ноопепт}}); developmental code name '''GVS-111'''), also known as '''''N''-phenylacetyl-<small>L</small>-prolylglycine ethyl ester''', is promoted as a [[nootropic]] and is a [[prodrug]] of [[cycloprolylglycine]].<ref name=Examine>{{cite web|title=Noopept Information|url=http://examine.com/supplements/Noopept/|publisher=[[Examine.com]]|accessdate=6 April 2017}}</ref><ref>{{cite journal|title=Proposed INN List 117|journal=WHO Drug Information|date=2017|volume=31|issue=2|page=308|url=http://www.who.int/medicines/publications/druginformation/innlists/PL117.pdf?ua=1}}</ref>

[[File:Noopept Box Front.jpg|thumb|right|Noopept Box Front]]
[[File:Noopept Blisterpack.JPG|thumb|right|Noopept [[blister pack]]]]

Its synthesis was first reported in 1996.<ref>{{Cite journal | doi = 10.1016/0223-5234(96)80448-X| title = Synthesis and antiamnesic activity of a series of N-acylprolyl-containing dipeptides| journal = European Journal of Medicinal Chemistry| volume = 31| issue = 2| pages = 151| year = 1996| last1 = Gudasheva| first1 = TA| last2 = Voronina| first2 = TA| last3 = Ostrovskaya| first3 = RU| last4 = Rozantsev| first4 = GG| last5 = Vasilevich| first5 = NI| last6 = Trofimov| first6 = SS| last7 = Kravchenko| first7 = EV| last8 = Skoldinov| first8 = AP| last9 = Seredenin| first9 = SB}}</ref> It is orally available, and as of 2017 its metabolism and elimination half-life were not well understood, as cycloprolylglycine had not been measured in humans following administration.<ref name=Examine/>

As of 2017 there had been many studies conducted in cells and in [[animal models]], and there had been one clinical trial with 41 subjects, which compared Noopept and piracetam in people with traumatic brain injury.<ref name=Examine/>

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800006775 Omberacetam - AdisInsight]

{{Antihyperkinetics}}
{{Racetams}}

{{DEFAULTSORT:Phenylacetyl-L-prolylglycine ethyl ester, N-}}

[[Category:Racetams]]
[[Category:Nootropics]]
[[Category:Pyrrolidines]]
[[Category:Ethyl esters]]
[[Category:Russian drugs]]